These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27834938)

  • 1. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.
    Spanoudakis E; Papoutselis M; Terpos E; Dimopoulos MA; Tsatalas C; Margaritis D; Rahemtulla A; Kotsianidis I; Karadimitris A
    Blood Cancer J; 2016 Nov; 6(11):e500. PubMed ID: 27834938
    [No Abstract]   [Full Text] [Related]  

  • 2. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.
    Fernández M; Pino AM; Figueroa P; Rodríguez JP
    J Cell Biochem; 2010 Sep; 111(1):130-7. PubMed ID: 20506157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes.
    Grcević D; Kusec R; Kovacić N; Lukić A; Lukić IK; Ivcević S; Nemet D; Seiwerth RS; Ostojić SK; Croucher PI; Marusić A
    Leuk Res; 2010 Jun; 34(6):742-51. PubMed ID: 19926132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
    Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
    Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL).
    Tilkeridis K; Kiziridis G; Ververidis A; Papoutselis M; Kotsianidis I; Kitsikidou G; Tousiaki NE; Drosos G; Kapetanou A; Rechova KV; Kazakos K; Spanoudakis E
    Med Sci Monit; 2019 Mar; 25():2151-2158. PubMed ID: 30903656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?
    Giuliani N; Colla S; Rizzoli V; Barillé-Nion S; Bataille R
    Cancer Res; 2004 Jan; 64(2):772-3; author reply 774-5. PubMed ID: 14744797
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
    Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
    Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
    [No Abstract]   [Full Text] [Related]  

  • 13. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of bone marrow microenvironment in regulation of AP-1 gene expression in multiple myeloma cells].
    Chen LJ; Xu JR; Zhou WH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):103-6. PubMed ID: 20137127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity.
    Alexandrakis MG; Passam FH; Pappa CA; Dambaki C; Sfakiotaki G; Alegakis AK; Kyriakou DS; Stathopoulos E
    Int J Immunopathol Pharmacol; 2004; 17(1):49-56. PubMed ID: 15000866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
    Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
    Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma in the marrow: pathogenesis and treatments.
    Fairfield H; Falank C; Avery L; Reagan MR
    Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
    Abdalla S; May PC; Garimberti E; Naresh KN
    Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
    [No Abstract]   [Full Text] [Related]  

  • 20. [Expression of pituitary tumor-transforming gene in patients with multiple myeloma].
    Wang Z; Lu QY; Chen P; Zhang P; Cong YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1143-5. PubMed ID: 17204181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.